SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma
Abstract Tumor-infiltrating myeloid cells (TIMs) are pivotal cell populations involved in the immunosuppressive tumor immune microenvironment (TIME). However, there has been little success in large-scale clinical trials of myeloid cell modulators. We aim to investigate potential molecular targets fo...
Saved in:
| Main Authors: | Da Huang, Min Xu, Hui Wang, Yufei Zhao, Zihao Zhang, Mincheng Yu, Mingqin Zhou, Jingying Pan, Hong Zeng, Zichuan Yu, Qiang Yu, Mengyuan Wu, Wenxin Xu, Binghai Zhou, Bo Zhang, Hui Li, Lei Guo, Peiyi Xie |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-06-01
|
| Series: | Cell Death and Disease |
| Online Access: | https://doi.org/10.1038/s41419-025-07779-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Blockade of CLEVER-1 restrains immune evasion and enhances anti-PD-1 immunotherapy in gastric cancer
by: Tianwei Xu, et al.
Published: (2025-05-01) -
FMO2+ cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma
by: Hui Li, et al.
Published: (2025-05-01) -
Enhancing tumor immunotherapy with smart nanoparticles for reprogramming macrophages and blocking the CD47/Sirpα pathway
by: Zubair Hussain, et al.
Published: (2025-06-01) -
Basic rules to respond to PD-1 blockade cancer immunotherapy
by: Antoni Ribas
Published: (2025-05-01) -
CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
by: Hongfei Wang, et al.
Published: (2020-10-01)